Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Chinese PLA General Hospital
Ossium Health, Inc.
City of Hope Medical Center
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Chinese PLA General Hospital
Thomas Jefferson University
Therapeutic Advances in Childhood Leukemia Consortium
Baptist Health South Florida
M.D. Anderson Cancer Center
Arog Pharmaceuticals, Inc.
Columbia University
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Washington University School of Medicine
Arog Pharmaceuticals, Inc.
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Children's Oncology Group
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
St. Petersburg State Pavlov Medical University
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Columbia University
Gruppo Italiano Malattie EMatologiche dell'Adulto
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
German CLL Study Group
UNC Lineberger Comprehensive Cancer Center
SCRI Development Innovations, LLC
Thomas Jefferson University
University Health Network, Toronto
Ann & Robert H Lurie Children's Hospital of Chicago
Roswell Park Cancer Institute